- Home
- PZC vs TLSI Comparison
PZC vs TLSI Comparison
Compare PZC & TLSI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PZC
- TLSI
- Stock Information
- Founded
- PZC 2002
- TLSI 2010
- Country
- PZC United States
- TLSI United States
- Employees
- PZC N/A
- TLSI N/A
- Industry
- PZC Investment Managers
- TLSI Medical Specialities
- Sector
- PZC Finance
- TLSI Health Care
- Exchange
- PZC Nasdaq
- TLSI Nasdaq
- Market Cap
- PZC 149.1M
- TLSI 160.4M
- IPO Year
- PZC N/A
- TLSI N/A
- Fundamental
- Price
- PZC $6.22
- TLSI $5.74
- Analyst Decision
- PZC
- TLSI Strong Buy
- Analyst Count
- PZC 0
- TLSI 6
- Target Price
- PZC N/A
- TLSI $11.75
- AVG Volume (30 Days)
- PZC 48.2K
- TLSI 57.4K
- Earning Date
- PZC 01-01-0001
- TLSI 05-14-2025
- Dividend Yield
- PZC 4.68%
- TLSI N/A
- EPS Growth
- PZC N/A
- TLSI N/A
- EPS
- PZC N/A
- TLSI N/A
- Revenue
- PZC N/A
- TLSI $29,431,000.00
- Revenue This Year
- PZC N/A
- TLSI $55.08
- Revenue Next Year
- PZC N/A
- TLSI $50.75
- P/E Ratio
- PZC N/A
- TLSI N/A
- Revenue Growth
- PZC N/A
- TLSI 58.99
- 52 Week Low
- PZC $6.30
- TLSI $3.50
- 52 Week High
- PZC $8.20
- TLSI $10.24
- Technical
- Relative Strength Index (RSI)
- PZC 29.20
- TLSI 59.91
- Support Level
- PZC $6.02
- TLSI $5.23
- Resistance Level
- PZC $6.74
- TLSI $5.66
- Average True Range (ATR)
- PZC 0.13
- TLSI 0.34
- MACD
- PZC -0.02
- TLSI 0.03
- Stochastic Oscillator
- PZC 30.77
- TLSI 92.94
About PZC PIMCO California Municipal Income Fund III of Beneficial Interest
PIMCO CA Muni Income Fund III operates as a closed-end management investment company. The investment objective of the fund is to seek to provide current income exempt from federal and California income tax. Its portfolio of investments includes investment in different sectors such as education, healthcare, industrial and others.
About TLSI TriSalus Life Sciences Inc.
TriSalus Life Sciences Inc is engaged in the research, development, and sales of innovative drug delivery technology and immune-oncology therapeutics to improve outcomes in difficult-to-treat liver and pancreatic cancer. It is developing and marketing two product lines Pressure Enabled Drug Delivery (PEDD) infusion systems, in use today, and an investigational agent, nelitolimod (SD-101), which shows potential to enhance immune system response in the treatment of hepatocellular cancer, pancreatic cancer and other liver solid tumors. TriNav is the newest therapy delivery device with SmartValve technology for the proprietary PEDD approach.